Although switching from adalimumab to the IL-17 inhibitor ixekizumab was initially considered, a within-class switch to another TNF inhibitor, certolizumab pegol, was ultimately chosen because of the strong evidence of TNF inhibitor effectiveness for uveitis. Here, IL17A is linked to uveitis.